Cancer Research | Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Induce Antitumor Immunity via Distinct Mechanisms

This study elucidates the unique mechanisms of two distinct strategies targeting TNFR2 in tumor immunotherapy, providing critical experimental evidence for designing combination immune checkpoint blockade regimens with PD-1 or CTLA-4.

 

Literature Overview

The article "Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity," published in Cancer Research, systematically explores the different modes of action of ligand-blocking and agonist antibodies when targeting TNFR2 and their capacity to remodel the tumor microenvironment. The article points out that although immune checkpoint inhibitors have transformed the cancer treatment landscape, response rates remain limited. As an emerging target, the pros and cons of TNFR2 agonist versus blockade strategies remain controversial. The study engineered two types of antibodies to deeply analyze their specific pathways for clearing regulatory T cells (Tregs) and activating effector T cells and NK cells in vivo.

Background Knowledge

This research primarily addresses the pain points of insufficient response rates and drug resistance in cancer immunotherapy. Currently, TNFR2 research faces challenges due to its complex biological functions: it is highly expressed on Tregs to maintain immune suppression, while simultaneously expressed on effector T cells and NK cells to provide co-stimulatory signals, making it difficult for a single strategy to address both. Furthermore, the specific contribution of FcγR interactions in antibody effects remains unclear. The study's entry point lies in using refined antibody engineering to distinguish between ligand-blocking and receptor-agonist mechanisms, and to clarify the weight of FcγR-dependent and independent pathways in tumor regression, thereby providing theoretical support for developing more precise immune checkpoint therapies.

 

 

Research Methods and Experiments

The authors constructed two antibodies targeting TNFR2: a ligand-blocking type (e.g., BI-1808/3F10) and a non-ligand-blocking agonist type (e.g., BI-1910/5A05). The experimental system covered various syngeneic mouse tumor models (including CT26, B16-F10, MC38, etc.) and utilized FcγR knockout mice (such as FcγR chain knockout, CD32 knockout) to解析 the mechanisms of antibody effects. Key evidence includes flow cytometry analysis of changes in tumor-infiltrating lymphocyte (TIL) subpopulations, single-cell RNA sequencing (scRNA-seq) to depict myeloid cell reprogramming trajectories, and in vitro co-culture experiments to verify Treg clearance and T cell activation capabilities.

In in vivo efficacy assessments, the study compared the inhibitory effects of different antibody isotypes (IgG1 vs IgG2a) and Fc mutants on tumor growth, combined with PD-1 antibody for combination therapy experiments. Using gene knockout cell lines and reporter cell lines, the authors further verified the activation of the NF-κB signaling pathway, confirming the direct activation capability of agonist antibodies in the absence of ligand blocking. These experimental designs rigorously separated ligand-blocking and Fc effector functions, providing solid data for mechanism analysis.

Key Conclusions and Perspectives

• Ligand-blocking antibodies (e.g., BI-1808) effectively clear intratumoral Tregs and reprogram myeloid cells to differentiate into pro-inflammatory macrophages and dendritic cells via an FcγR-dependent mechanism; this process requires the synergistic action of both inhibitory and activating FcγRs.
• Agonist antibodies (e.g., BI-1910) primarily induce tumor regression through FcγR-independent or partially dependent mechanisms by directly co-stimulating T cells and NK cells, without fully relying on Treg clearance.
• Both strategies ultimately converge on activating tumor-specific CD8+ T cells to mediate tumor rejection, and both show significant synergistic effects when combined with PD-1 inhibitors.
• Preclinical data indicate that optimizing the TNFR2 target requires selecting the best antibody isotype based on the functional mode: IgG1 is preferred for ligand-blocking antibodies, while agonist antibodies perform better under specific isotypes.

Research Significance and Prospects

This discovery has profound implications for drug development, indicating that targeting TNFR2 is not limited to a single mechanism; one can choose ligand-blocking or agonist strategies based on tumor microenvironment characteristics. For clinical monitoring, the study suggests paying attention to dual biomarkers of Treg depletion and effector cell activation. In disease modeling, the research emphasizes the importance of using FcγR-deficient models to evaluate antibody efficacy, avoiding mechanism misinterpretation due to species differences. In the future, the design of combination immunotherapies for solid tumors should fully consider the dual regulatory characteristics of TNFR2.

 

 

Conclusion

Through rigorous in vivo and in vitro experiments, this study thoroughly clarifies two distinct yet highly effective strategies for targeting TNFR2. Ligand-blocking antibodies function by reshaping the inhibitory network within the tumor microenvironment, particularly by clearing Tregs and activating myeloid cells; whereas agonist antibodies directly empower effector immune cells. This finding not only resolves the mechanistic controversy surrounding TNFR2 as a target but also provides new combinatorial approaches for cancer immunotherapy. From laboratory to clinical translation, the differentiated mechanisms of these two antibodies (BI-1808 and BI-1910) offer the possibility of precision treatment for patient populations with different immune characteristics, with the potential to break through the efficacy bottlenecks of existing immune checkpoint inhibitors and become a cornerstone of future tumor immunotherapy systems.

 

Linda Mårtensson, Petra Holmkvist, Kirstie L Cleary, Björn Frendéus, and Ingrid Teige. Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity. Cancer Research.